Knockdown of Antisense Noncoding Mitochondrial RNA Reduces Tumorigenicity of Patient-Derived Clear Cell Renal Carcinoma Cells in an Orthotopic Xenograft Mouse Model

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Clear cell renal cell carcinoma (ccRCC) is the most common kidney cancer.
• Treatment of ccRCC is challenging due to resistance to current therapies.
• Antisense noncoding mitochondrial RNAs (ASncmtRNAs) are implicated in cancer cell proliferation.

Purpose of the Study:

• To investigate the efficacy of ASncmtRNA knockdown in patient-derived ccRCC cells.
• To evaluate ASncmtRNA knockdown in an in vivo ccRCC model.
• To assess ASncmtRNA knockdown as a potential therapeutic strategy for ccRCC.

Main Methods:

• Primary ccRCC cells were cultured from patient tumors.
• ASncmtRNAs were knocked down using antisense oligonucleotides in vitro and in vivo.
• An orthotopic xenograft mouse model (NOD/SCID) was used to assess tumor growth.
• Tumor growth and cell proliferation/apoptosis were analyzed.

Main Results:

• Patient-derived ccRCC cells exhibited reduced proliferation and increased apoptosis upon ASncmtRNA knockdown.
• In vivo treatment significantly reduced tumor growth in the orthotopic xenograft model.
• ASncmtRNA knockdown demonstrated consistent anti-tumor effects in patient-derived cells and models.

Conclusions:

• Knockdown of ASncmtRNAs is effective against primary and metastatic ccRCC cells.
• This approach shows promise as a novel therapeutic strategy for ccRCC patients.
• Targeting ASncmtRNAs offers a potential avenue to overcome treatment resistance in ccRCC.